Atyr PHARMA (NASDAQ:ATYR) Announces Earnings Results

Atyr PHARMA (NASDAQ:ATYRGet Free Report) posted its earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05, Zacks reports.

Atyr PHARMA Stock Down 0.5 %

NASDAQ ATYR opened at $3.97 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $3.06. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The company has a market capitalization of $333.25 million, a P/E ratio of -4.22 and a beta of 0.98.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Friday. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Atyr PHARMA presently has an average rating of “Buy” and an average target price of $18.60.

Read Our Latest Research Report on ATYR

Atyr PHARMA Company Profile

(Get Free Report)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Further Reading

Earnings History for Atyr PHARMA (NASDAQ:ATYR)

Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.